ClinicalTrials.gg

Program

NW-301V

A development code.

Its studies are mostly in Adenocarcinoma of Lung, led by Neowise Biotechnology.

Furthest: phase 1, since Sep 30, 20261 company-led study, 1 open or runningNext primary completion: Mar 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neowise Biotechnology11 open or runningphase 1since Sep 30, 2026Sep 30, 2026Mar 2030phase 1 · NCT07875920

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2026First study: phase 1 study in Adenocarcinoma of LungFirst studyNCT07875920 · 66 planned · China

Ahead

  1. Mar 2030Primary completion: phase 1 study in Adenocarcinoma of LungNCT07875920

TargetBeta

KRAS →read by rule
“NW-301V is an autologous TCR-T cell therapy targeting KRAS G12V in the context of HLA-A\*11:01, administered intravenously after lymphodepletion.”study text, by rule · the study

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07875920Adenocarcinoma of Lung · China1Not yet recruitingMar 203066

How it is read

Names in the registry

  • “NW-301V”, 1 entry

Codes read as this program: NW301V.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.